Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout ...
The 2027 budget that the Trump administration released on Friday is in many ways a repeat of last year’s proposal: It ...
Even as therapies improve, a startling number of cancer patients are not getting genomic tests that could improve their chance of survival.
Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company.
The FDA used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs ...
FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage ...
Read more from STAT contributor Brianna Abbott on the popular vote winner. And STAT’s Amanda Erickson, who edits this very newsletter, has a dispatch on the research our editors chose as the best ...
People who have been stable for years are suddenly re-exposed to risk — not because their disease worsened, but because their ...
Health care will become autonomous because the survival of health systems depends upon it,” writes former Geisinger CEO Glenn ...
Gilead is buying the German biotech Tubulis for more than $3 billion, a move that will expand its oncology pipeline.
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year ...
The researchers identified a driving force behind the condition, opening up a potential target for new therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results